Cancer Researchers Liotta and Petricoin to Discuss Personalized Therapy

Posted: September 8, 2010 at 1:59 pm

Lance Liotta, left, and Emanuel Petricoin III.

Lance Liotta and Emanuel Petricoin III, codirectors of Mason’s Center for Applied Proteomics and Molecular Medicine, will present “The Dawn of the Age of Personalized Therapy: Proteomic Technologies and Strategies for Implementation” on Tuesday, Sept. 14, at 7 p.m. at the Hylton Performing Arts Center on the Prince William Campus.

According to the researchers, the field of molecular medicine is moving beyond genomics to proteomics and a systems-biology approach to disease. While DNA is the information archive, proteins do all of the work of the cell and ultimately dictate all biological processes.

Importantly, the researchers explain, it is the proteins themselves that are most often the drug targets for therapy and new markers for detection. They believe strongly that the future of patient-tailored therapy and early detection will rely on new proteomic approaches in order to discover and profile proteins within the blood and the cancer cells of the patient.

To address this need, Liotta and Petricoin have developed a cadre of new proteomic and nanotechnologies to translate basic science discoveries to patient benefit. This presentation will summarize how their program has taken the transition from research at the bench to implementation at the bedside.

This lecture inaugurates the Vision Series at the Prince William Campus. The lecture will be followed by an informal reception with light refreshments with the speakers. The lecture is free but tickets are required. For more information and to reserve tickets for the Prince William event, see the website.

Write to mediarel at